Pharvaris is moving forward with Phase 3 clinical trials. The RAPIDe-3 study (NCT06343779) is testing an immediate-release formulation of deucrictibant, called PHVS416, as an on-demand therapy for HAE. Recruitment is ongoing at sites in the U.S., Puerto Rico, South Korea, and Germany.

Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions.

At the World AMR Congress, Recce Pharmaceuticals contributes by making strides with a synthetic compound designed to target bacterial mutations, underscoring the need for innovation in addressing antimicrobial resistance (AMR). “Our compound is entirely synthetic,” Graham said. “We started with first principles, designing a compound that remains effective with repeated use.”

This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.

Biotech company MindMed is shoring up its cash stockpile to inch its psychedelic therapies towards approval after the feds’ recent thumbs-down of using MDMA to treat post-traumatic stress disorder.

Spinogenix founder Dr Stella Sarraf joined Sky News Business Editor Ross Greenwood to discuss the ongoing groundbreaking trial.

Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency.

Aligos is developing a capsid assembly modulator, ALG-000184, as a hepatitis B treatment. The South San Francisco, California-headquartered company presented data for the therapy at the June 2024 European Association of Liver Disease (EASL) Congress in Italy.